April 27, 2022 09:50 AM EDTUpdated 10:03 AM
FDA+
Manufacturing

Fen­nec looks for FDA ap­proval for hear­ing loss drug haunt­ed by man­u­fac­tur­ing prob­lems

Lei Lei Wu

News Reporter

Third time’s the charm. Maybe.

Fen­nec Phar­ma­ceu­ti­cals an­nounced this morn­ing that the FDA is re­view­ing its NDA for its on­ly can­di­date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times